Abstract Library

#4646 Dysregulated miRNA in patients with GEP-NEN and potential role as circulating biomarker

Introduction: Neuroendocrine neoplasms (NENs) are a class of rare and molecularly extremely heterogeneous tumours. NENs arise predominantly in the gastrointestinal (GEP) and pulmonary tracts but can also involve thyroid and breast. NENs often present with non-specific symptoms and lack early specific biomarkers, leading to frequent metastatic diagnoses and primary site challenges.

Conference:

Presenting Author:

Authors: Di Mauro A, Clemente O, Cannella L, Della Vittoria G, Neri G,

Keywords: neuroendocrine tumour, miRNome profiling, biomarker, gep-net, molecular biology,

#4557 miR-1290 and miR-320c regulate cell proliferation and predict patient prognosis in neuroendocrine carcinomas

Introduction: The biology of neuroendocrine carcinomas (NECs) remains largely unknown, limiting the use of biomarkers for patient stratification and therapy response prediction in clinical practice.

Conference:

Presenting Author: Liverani C

Authors: Liverani C, Sgolacchia F, Bongiovanni A, Calabrese C, Vanni S,

Keywords: biomarker, miRNAs, neuroendocrine carcinoma,

#4227 Evaluation of circulating extracellular vesicles as suitable prognostic markers in MEN1-associated non-functioning pancreatic neuroendocrine neoplasia

Introduction: Non-functioning pancreatic neuroendocrine neoplasias (NF-pNENs) significantly contribute to premature death of multiple endocrine neoplasia type 1 (MEN1) patients. Reliable prognostic markers for disease progression are lacking. Circulating liquid biomarkers, including microRNAs and Long-non-Coding (LnC) RNAs in extracellular vesicles, are emerging as new prognostic tools.

Conference:

Presenting Author:

Authors: Manoharan J, Khizanishvili N, Krasser-Gercke N, Albers M, Mintziras I,

Keywords: Multiple endokrine neoplasia type 1, Extracellular vesicles, Non-functioning pancreatic neuroendocrine neoplasia, exosomal-LnC-RNA NEAT1, exosomal miRNA451a,

#4036 Metformin inhibits small intestinal neuroendocrine tumor proliferation in vivo

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow-growing, with most patients being diagnosed at a late stage with distant metastases. Metformin has been hypothesized as a potential anti-tumor agent by several studies in the past few years. This has been further confirmed by experimental studies in which metformin has inhibited cancer cell growth in different cancers, and we recently demonstrated that metformin treatment repressed the cell viability of SI-NET cells and inhibited the proliferation of cell spheroids.

Conference:

Presenting Author:

Authors: Axling F, Hellman P, Norlén O, Stålberg P, Barazeghi E,

Keywords: neuroendocrine neoplasm, SI-NET, in vivo model, metformin, RNA-seq, miRNA-seq, xenograft,

#4011 Differences in the microRNA expression of G1 and G2 pancreatic neuroendocrine tumors

Introduction: Targeted testing of microRNAs implicated in the biology of pancreatic neuroendocrine tumors (PNET) was performed via RT-QPCR to uncover differentially expressed microRNAs that could be used as diagnostic markers characteristic for tumor grade.

Conference:

Presenting Author:

Authors: Nyirő G, Szeredás B, Vékony B, Borka K, Zalatnai A,

Keywords: miRNA expression, PNET G1 and G2, RT-QPCR, hsa-miR-130b-3p, hsa-miR-194-5p, hsa-miR-96-5p, hsa-miR-106b, FFPE tissue,